Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9178
+0.01481.64%
Post-market: 0.92200.0042+0.46%19:58 EDT
Volume:7.50M
Turnover:6.85M
Market Cap:254.33M
PE:-8.25
High:0.9362
Open:0.9082
Low:0.8952
Close:0.9030
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.23
T/O Rate:2.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:10.17
PE(LYR):-44.16

Loading ...

Akebia Therapeutics Schedules Quarterly Results Release, Conference Call

Reuters
·
Jul 29

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Jul 29

Monopar Adds Ex-kalvista CCO Nicole Sweeny to Board

Reuters
·
Jul 20

Akebia Grants 125,600 Inducement Stock Options to New Hires at USD 1.14 a Share

Reuters
·
Jul 03

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Akebia Therapeutics Price Target Maintained with a $6.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 01

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)

TIPRANKS
·
Jul 01

Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis

MT Newswires Live
·
Jun 30

Akebia Therapeutics - Usrc Kidney Research Stops Voice Trial After Interim Analysis Shows Improved Safety with Vafseo

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - Voice Trial Meets Stopping Criteria with Win Odds of 1.16 as of June 1, 2026

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - no Significant Difference in Mortality: Vafseo 8.77% vs Esa 8.78% Per 100 Patient-years

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch

Simply Wall St.
·
Jun 24

Akebia Therapeutics shareholders approved authorized share increase amendment at annual meeting

Reuters
·
Jun 23

Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease

MT Newswires Live
·
Jun 10

Akebia says new Vafseo dosing patent is listed in FDA Orange Book

Reuters
·
Jun 10

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

GlobeNewswire
·
Jun 10

Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each

Reuters
·
Jun 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20